Clinical effect of Jinlong capsules combined with Western medicine treatment in treatment of primary liver cancer: A Meta-analysis / 临床肝胆病杂志

@#ObjectiveTo investigate the clinical effect and adverse events of Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer. MethodsPubMed, The Cochrane library, CNKI, Wanfang Data, CBM, and VIP were searched for randomized controlled trials (RCTs) on Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer published up to May 2019. The patients treated with Jinlong capsules combined with Western medicine treatment were enrolled as intervention group, and those treated with Western medicine treatment alone were enrolled as control group. Data extraction and quality assessment were performed, and RevMan 5.3 was used to perform the Meta-analysis with a fixed or random effects model. ResultsA total of 26 RCTs were included, with a total of 2318 patients (1175 patients in the intervention group and 1143 patients in the control group). The results of the Meta-analysis showed that compared with Western medicine treatment alone, Jinlong capsules combined with Western medicine treatment had significant increases in response rate (relative risk ［RR］=1.36, 95% confidence interval ［CI］: 125-1.49, P＜0.001), 1-year survival rate (RR=1.29, 95%CI: 1.14-1.47, P＜0.001), Karnofsky Performance Scale score (RR=137, 95%CI: 1.19-1.59, P＜0.001), peripheral blood CD3+ T lymphocytes (mean difference ［MD］=11.18, 95%CI: 268-1968, P=0.01), CD4+ T lymphocytes (MD=6.43, 95%CI: 3.82-9.05, P＜0.001), and CD4+/CD8+ ratio (MD=0.31, 95%CI: 026-0.36, P＜0.001), as well as significant reductions in rate of progression (RR=0.41, 95%CI: 0.29-0.57, P＜0001), rate of leucopenia (RR=0.65, 95%CI: 0.57-0.75, P＜0.001), incidence rate of gastrointestinal reactions (RR=0.72, 95%CI: 059-088, P=0.001), and peripheral blood CD8+ T lymphocytes (MD=-4.68, 95% CI: -5.84 to -3.51, P＜0001). ConclusionJinlong capsules combined with Western medicine treatment has a marked clinical effect in the treatment of advanced primary liver cancer with few adverse events and thus holds promise for clinical application.

Preliminary study of determination of Shougong in Jinlong Capsules based on fluorescence quantitative PCR method / 中国中药杂志

A pair of species-specific primer (GZG1/GZG2) based on COⅠ sequence regions for identification of Gekko chinensis were designed. A fluorescent quantitative PCR method was established to identify and quantify G. chinensis from Jinlong Capsules Formula. A standard curve for quantitative analysis of G. chinensis was established (the standard curve equation: y=-3.012 7x+34.501, y is Ct value, x is lg N, N is the copies of COⅠ fragment from G. chinensis). Samples included G. chinensis appeared amplification, while falsify group (not included G. chinensis) and negative control did not have amplification products. The copy number of COⅠ region of G. chinensis was respectively 11.511×10⁶, 6.416×10⁶, 2.553×10⁶ copies/μL in all quality goods, quality goods-adulterants 1:1, quality goods-adulterants 1:4. The results accorded with proportion of adding amount roughly. This study can provide a new strategy for quality control of Chinese patent medicine containing animal drug ingredients.

Study of anti-cancer traditional Chinese medicine using systems biology technology / 中国肿瘤临床

This article focuses on the research of molecular mechanism of brain tumor treatment using the Jinlong capsule via system biology technology. Methods:Human Genome U133 Plus 2.0 gene chip was used to detect the genes of samples, in-cluding the brain tumor tissues of nude mice after Jinlong capsule intervention and those of blank control group mice. Differentially ex-pressed genes were identified based on fold change between the two groups. To identify the upstream regulators of the response signa-tures, the differentially expressed genes were subjected to interactome analysis by one-step overconnectivity test and multi-step hidden node algorithm. A set of genes preferentially connected to differentially expressed genes via direct interactions and pathways (called to-pologically significant genes) was generated. Concurrent pathway enrichment analysis on key pathways, processes, and functional units of both differentially expressed genes and topologically significant genes was performed to identify the most likely signaling pathways connecting regulators and effector genes. Finally, condition-specific networks (called causal network) were built to model molecular events by using a set of manually annotated protein interactions, pathways, and proteins and a toolkit of algorithms and filters on Meta-Core platform. Results:A total of 37 differentially expressed genes have been identified between Jinlong capsule-treated sample and ve-hicle sample with fold change of 2. Connection analysis identified 106 topologically significant genes. The main feature of the causal network is stimulation of neural cell specific genes that regulate normal cell physiology, particularly developmental processes and apop-tosis. Another important effect of the Jinlong capsule is its inhibition of the gene markers of interferon response, suggesting signaling in-hibition, followed by de-activation of immune response. Conclusion:Jinlong capsule exerts an anti-neoplastic effect by inducing stimu-lation of neural cell and by inhibiting interferon signal transduction.